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1. Introduction
1.1 CXC Receptor 4 
Chemokines, a family of small (8–14kDa) proteins secreted by cells, play a 
crucial role in the host immune defense system and are the major regulators 
involved in cell activation, differentiation and trafficking [26;50]. Depending on 
the spacing of their first two cysteine residues, chemokines are divided into 
four groups: C, CC, CXC and CX3C chemokines. Chemokines bind and 
activate a subset of specific G-protein-coupled seven-span transmembrane 
receptors (chemokine receptor) on the surface of target cells. Up to now, 
nearly nineteen distinct chemokine receptors have been reported in mammals. 
Similarly as described for the ligands, their cognate receptors are divided into 
four groups (CC, CXC, CX3C and XC chemokine receptors) according to the 
chemokines they bind. Although most chemokines bind to multiple receptors 
and some receptors bind to more than one chemokine, the C-X-C chemokine 
receptor type 4 (CXCR4) takes stromal cell-derived factor-1α (SDF-1α) as its 
unique ligand. Reportedly, SDF-1α could also bind to CXCR7/RDC1, however 
this mechanism was not well defined [64;96]. 
CXCR4, also known as fusin or CD184, is a small protein encoded by the 
human CXCR4 gene. CXCR4 has a short, acidic extracellular N-terminal end, 
seven helical transmembrane domains with three intracellular hydrophilic 
loops [2]. As typically observed for G-protein linked receptors, the intracellular 
C-terminus of CXCR4 interacts with G-proteins and thereby enables 
transmembrane cell signaling after SDF-1α binding. CXCR4/SDF-1α activates 
numerous intracellular signaling pathways [28;63;91;97], such as the pI3K/AKT, 
cAMP/PKA, Ras/MAPK and DG/Ca2+-PKC pathways, influencing cell 
chemotaxis, migration, proliferation, apoptosis and adhesion (Fig. 1).  
CXCR4 is also known as a co-receptor for HIV/SIV during viral entry 
[17;18;73]. CXCR4/SDF-1α plays a central role in hematopoietic stem cell 
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homing and bone marrow release. Knockout of CXCR4 or SDF-1α in 
transgenic mice results in embryonic lethality and underscores its critical role 
in the development of the nervous, cardiovascular as well as the hematopoietic 
system [57;79]. CXCR4 is found over expressed in a wide variety of human 
cancers, such as lung, pancreatic, breast, prostate and kidney cancer 
[4;5;30;48;62;88]. It is not surprising that more and more evidence indicates 
CXCR4/SDF-1α to play an important role in tumor development since it not 
only promotes cancer cell proliferation, migration but also metastasis and 
tumor angiogenesis [74;77].  
Two CXCR4 variants (CXCR4 and CXCR4-Lo) have been identified so far. 
CXCR4-Lo, also known as variant 1, differs from the known human CXCR4 
(variant 2) by the first 9 aa in the N-terminal extracellular domain of the 
receptor (Fig. 2), which is close to the region (aa 2-25) critical for SDF-1α 
binding [25;36;95]. The function of CXCR4-Lo is not well understood. However 
single reports see a lower tissue expression and reduced response to its ligand 
SDF-1α [36].  
Figure 1. CXCR4/SDF-1α signal pathway. CXCR4/SDF-1α 
activates G-proteins and subsequently enables transmembrane 
cell signaling [29;65;96;101]. 
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1.2 Negative regulatory factor (Nef) 
Negative regulatory factor (Nef) is a 27kDa, N-terminal myristoylated 
protein. Nef is one of four accessory proteins expressed by primate 
lentiviruses, such as human immunodeficiency viruses -1 and -2 (HIV-1 and 
HIV-2) and simian immunodeficiency virus (SIV) (Fig. 3) [27].  
Although Nef was originally called "negative factor," subsequent studies 
revealed that Nef was essential for high viral loads thereby promoting the 
development of acquired immunodeficiency syndrome (AIDS). Nef enhances 
viral infectivity during the early stage of the infection [1;92]. It is found highly 
expressed during the early phase of HIV infection and its mRNA is estimated to 
represent 75% of the early viral mRNA load [37;47]. HIV-1 harboring wild type 
Nef was found to be 5 to 20 times more infective than Nef-defective HIV-1 
[19;45]. Nef can down-modulate cell surface MHC-I, MHC-II and CD28 to 
promote immune-escape of HIV infected cells since down modulation of these 
surface markers reduces viral antigen presentation at the cell surface 
Figure 2. CXCR4 transcript variants. CXCR4-Lo differs from 
CXCR4 by the first 9 aa in its N-terminus which is close to the SDF-1 
binding site. 
*Figure is designed with the MultAlin software tool [21]. 
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[9;33;51;76;82;83;86;87]. Correspondingly, lower surface levels of CD28 
ensure that infected cells can not provide effective help following TCR 
engagement [7;89]. Moreover, Nef can not only promote apoptosis in T cells 
[80] but also is able to protect infected cells from apoptosis by inhibiting its 
internal [12;31;35] and external death signals [101]. Reportedly Nef can also 
inhibit p53 dependent apoptosis [34].  
Nef is known to down modulate CD4, the main receptor for HIV/SIV as well 
as its co-receptor CCR5, aiming to prevent a lethal viral superinfection [65]. 
Nef was also reported as a wide-range regulator of chemokine receptors being 
able to reduce all surface levels of CC- and CXC- family members by up to 
92% [66]. Nef down regulates CXCR4 from the surface of target cells and, as 
described for CD4 and CCR5, promotes resistance of the infected cells to 
superinfection [94;100]. Nef from different viral strains exhibits large 
differences in their ability to down regulate CXCR4. For example, Hrecka et al. 
[40] observed a strong down modulating effect of Nef from SIVmac239 and HIV-2 
on cell surface CXCR4 and SDF-1α dependent lymphocyte metastasis. In 
Figure 3. Proteins encoded by HIV/SIV. Except for the three 
prototypical retroviral proteins (Gag, Pol and Env) and two regulatory 
proteins (Tat, Rev), HIV/SIV also encodes four accessory proteins called 
Vif, Vpr, Vpu and Nef.  
*Picture modified from Frankel et al. [27]. 
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contrast, HIV-1 Nef did not exhibit a comparable effect. Similar effects could 
also be observed in CHO cells [94]. However, Venzke et al. did not observe 
such differences between HIV and SIV Nef [55]. 
Several studies addressed the mechanism underlying the Nef dependent 
down regulation of these receptors. The tyrosine- and dileucine- based motifs 
near the N-terminus and the C-terminal flexible loop in SIV- or HIV-2- Nef play 
a critical role for Nef dependent receptor internalization [8;10;55;78]. Mutations 
of critical residues in these regions could decrease cell surface internalization 
of CD4 and viral infectivity [58].  
1.3 Aim of the study 
Since Nef can down modulate surface CXCR4 in CD4+ T cells, it is of 
interest to evaluate if Nef can also affect expression of this receptor in CXCR4 
positive tumor cells and subsequently influence tumor-promoting features such 
as proliferation, migration and angiogenesis.  
In this study, the CXCR4 positive tumor cells were transfected with Nef from 
SIVmac239 (SIV-Nef) and cell surface receptor levels were monitored by FACS 
analysis. Real time proliferation and migration of Nef transfected cells were 
measured with the xCELLigence system. Effects of Nef on angiogenesis were 
evaluated by an in vitro tube formation assay using HUVEC cells and its 
influence on cell signaling was evaluated in this study. Our data indicate that 
SIV-Nef could serve as an interesting experimental tool for the study of 
CXCR4-expressing tumors and potentially could help to pinpoint new 
therapeutic approaches for the treatment of CXCR4 positive tumors.
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2. Materials 
2.1 Chemicals and reagents 
 Acetic acid glacial 100% (Merck,Darmstadt) 
 Agar, Select (Sigma-Aldrich, St. Louis, MO, USA) 
 Agarose (Invitrogen Life Technologies, Scotland, UK) 
 Ammonium persulfate (APS) (Sigma-Aldrich, St. Louis, MO, USA) 
 Ampicillin (Sigma-Aldrich, St. Louis, MO, USA) 
 BSA (PAA Laboratories, Pasching, Austria) 
 DAPI (Roche Diagnostics, Indianapolis, IN, USA) 
 DMEM (PAA Laboratories, Pasching, Austria) 
 DNA EcoRI Digest (DNA Marker) (New England Bio Labs, Beverly, MA, 
USA) 
 DNA Hind III Digest (DNA Marker) (New England Bio Labs, Beverly, MA, 
USA) 
 Dulbecco’s Phosphate-Buffered Saline PBS (Biochrom AG, Berlin) 
 Dodecylsulfate (Serva Electrophoresis, Heidelberg) 
 EDTA (Roth, Karlsruhe) 
 Ethanol (Roth, Karsruhe) 
 Ethidiumbromide 1% ( Roth, Karlsruhe) 
 Fluorescent Mounting Medium ( Dako Cytomation , Carpinteria, Foster 
City, CA, USA) 
 Glycerol (Roth, Karlsruhe) 
 Isopropanol (Acros Organics, Belgium, NJ, USA) 
 Isopropyl--D-Thiogalacto-Pyranoside (IPTG) (Sigma-Aldrich, St. Louis, 
MO, USA) 
 Skim milk powder (Merck, Darmstadt) 
 2-Mercapto-Ethanol (Sigma-Aldrich, St. Louis, MO, USA)  
 Methanol (Sigma-Aldrich, St. Louis, MO, USA)  
 Sodium-Chloride (Merck, Darmstadt) 
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 Sodiumhydroxide (Fisher Scientific, Leicestershire, UK) 
 Nonidet P40 Substitute NP40 (Sigma-Aldrich, St. Louis, MO, USA) 
 Penicillin-Streptomycin-Lincomycin (Invitrogen Life Technologies, 
Karlsruhe) 
 Pierce ECL Western Blotting Substrate (Thermo Scientific, Rockford, IL, 
USA) 
 Precision Plus Protein All Blue Standards (Bio-Rad Laboratories, 
München) 
 Propidium Iodide (Sigma-Aldrich, St. Louis, MO, USA)  
 Protein Assay Dye Reagent Concentrate (Bio-Rad Laboratories, 
München) 
 Medical X-ray film (Agfa-Gevaert, Mortsel, Belgium) 
 Ribonuclease A (Sigma-Aldrich, St. Louis, MO, USA)  
 Rotiphorese  Gel 30 (Roth, Karlsruhe) 
 Hydrochlorid acid (Merck, Darmstadt) 
 Tetramethylethylenediamine, TEMED (Roth, Karlsruhe) 
 Tris-HCL (Roth, Kalsruhe) 
 Trypsin-EDTA (PAA, Laboratories, Pasching, Austria) 
 Tryptone EZMix (Sigma-Aldrich, St. Louis, MO, USA)  
 Tween-20 (Roth, Karlsruhe) 
 X-Gal (Sigma-Aldrich, St. Louis, MO, USA) 
 Yeast Extract EZMix (Sigma-Aldrich, St. Louis, MO, USA)  
2.2 Culture media 
 Dulbecco's Modified Eagle Medium (DMEM) supplemented with:  
10% Fetal Calf Serum (FCS) 
1% L-glutamine  
100U/ml penicillin 
100mg/ml streptomycin 
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 EGM®-2 Endothelial Cell Growth Medium-2 (Lonza, Switzerland) 
supplemented with:  
Growth factors, cytokines, and other supplements (SingleQuots® Kit, 
CC-4176, Lonza) 
 Lysogeny broth (LB) Medium (pH 7.0) for 1L: 
NaCl 5.0g 
Yeast 5.0g 
Tryptone 10.0g 
Agar-Agar (only for LB plate) 15.0g 
                                          
2.3 Cell lines 
 African Green Monkey SV40-transformed kidney fibroblast cell line 
(COS-7) 
 CXCR4 expressing cell line designated HeLa-ACC, see 3.2 
 Human Umbilical Vein Endothelial Cells  
(HUVEC, C-003-5C, Life Technologies Corporation, Carlsbad, CA, 
USA) 
 Madine-Darby canine kidney cell-clone 7 (MDCK-C7) 
 Melanoma cell line (A7) 
 HeLa cell line 
2.4 Antibodies 
2.4.1 Primary antibodies 
 Anti-β-Actin   (Sigma, St. Louis, MO,USA) 
 Anti-Erk1/2   (Upstate, Lake Placid, NY, USA) 
 Anti- Erk1/2-phospho (Sigma St. Louis, MO,USA) 
 Anti-CXCR4    (Abcam plc, Cambridge, UK) 
 Anti-Cyclin-D1  (Santa Cruz Biotechnology, Santa Cruz, CA, USA) 
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 Anti-SIV-Nef   (Santa Cruz Biotechnology, Santa Cruz, CA, USA) 
 Anti-Caspase 3   (Santa Cruz Biotechnology, Santa Cruz, CA, USA) 
 Anti-Stat3  (Santa Cruz Biotechnology, Santa Cruz, CA, USA) 
 Anti-Stat3-phospho  (Santa Cruz Biotechnology, Santa Cruz, CA, USA) 
2.4.2 Secondary antibodies 
 Anti-mouse-IgG, HRP-linked antibody (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) 
 Anti-rabbit-IgG, HRP-linked antibody (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA) 
 Anti-goat-IgG, HRP-linked antibody (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA) 
2.5 Kits 
 First strand cDNA-Synthesis Kit (Roche Diagnostics, Mannheim) 
 QIAgen RNeasy Mini Kit (Qiagen, Hilden) 
 QIAquick Gel Extraction Kit (Qiagen, Hilden) 
 QIAprep spin Miniprep Kit (Qiagen, Hilden) 
 QIAprep plasmid Midiprep Kit (Qiagen, Hilden) 
 Blood & Cell Culture DNA Mini Kit (13323, Qiagen, Hilden) 
 REDTaq® ReadyMixTM PCR Reaction Mix (Sigma-Aldrich, St. Louis, MO, 
USA) 
 StrataClone PCR Cloning Kit (Stratagene Products Division, La Jolla, 
CA, USA) 
 Endothelial Tube Formation Assay (in Vitro Angiogenesis) kit  
(Cell Biolabs Inc., San Diego, CA, USA ) 
 In vitro angiogenesis kit (Cell Biolabs Inc., San Diego, CA, USA) 
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 CXCR4 specific siRNA (sc-35421) (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA ) 
 Control scrambled RNA (1027281) (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA ) 
 2.6 Buffers: 
2.6.1 PCR buffers: 
 5x TAE-buffer (Tris-Acetat-EDTA):  
Trisbase 24.2g 
Acetic acid glacial 5.7ml 
EDTA 3.7g 
H2O 1.0L 
 DNA- Loading buffer (6x buffer for agarose gel electrophoresis): 
Glycerol 5.0ml 
Bromophenol blue 40.0mg 
Xylene cyanol 40.0mg 
EDTA 3.7mg 
 Agarose gel (1%): 
Agarose 1.0g 
1x TAE buffer 100.0ml 
Ethidium bromide 1% 6.0µl 
 DNA size standard: 
100bp/1kb ladder  1.0μl 
H2O 9.0μl 
6 x DNA loading buffer   2.0μl 
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2.6.2 Buffers for SDS-PAGE and Western blot analysis: 
 Lysis-buffer (NP40): 
Tris-HCl pH 7.5 20.0mM 
NaCl 50.0mM 
Glycerol   10% 
Nonidet P40 1% 
 10 x Electrophoresis-buffer for SDS-PAGE: 
Tris Base 60.4g 
Glycin 76.0g 
SDS 20.0g 
H2O 2.0L 
 Transfer buffer (pH 8.3): 
Tris 3.03g 
Glycin 14.4g 
H2O 2.0L 
 Blocking buffer: 
Skim milk powder 3.0g 
PBS 100.0ml 
 SDS polyacrylamide gel solution (Table 1): 
Table 1. SDS polyacrylamide gel solution 
SDS 
Gel 
(X4) 
Total 
Volume 
(ml) 
Water 
(ml) 
Polyacrylamide 
(ml) 
1.5M 
Tris 
(ml) 
0.5M 
Tris 
(ml) 
10% 
SDS 
(ml) 
10% 
APS 
(ml) 
TEMED 
(μl) 
6% 
(Stack) 
20 10.8 4.0 0 5 0.2 0.2 20 
10% 40 15.8 13.4 10 0 0.4 0.4 40 
12% 40 12.8 16.4 10 0 0.4 0.4 40 
Materials 
- 12 -   
 
2.6.3 Incubation solution for immunocytochemistry (ICC): 
PBS 100.0ml 
BSA 3.0g 
NP40 300.0µl 
2.7 Oligo Primers 
Primers used in this study (Table 2) were designed using the Primer 
Premier 5.0 software and online blast (www.ncbi.nlm.gov/tools/primer-blast). 
Primers were obtained from Invitrogen (Life Technologies GmbH, Darmstadt). 
2.8 Equipment  
 Autoradiography cassette Agfa, Köln 
 BD FACS Calibur Flow Cytometer Becton Dickinson, Heidelberg 
 Cell culture hood Heraeus, Hanau 
 Centrifuge (Labofuge 400R) Medifuge Heraeus, Hanau 
 Centrifuge universal (30 F) Hettich, Tuttllingen 
 Epithelial volt-ohmmeter for TEER WPI, Sarasota, FL, USA 
 Eppendorf Bio Photometer Eppendorf-Netheler-Hinz, 
Hamburg 
 E-Plate for xCELLigence system Roche, Mannheim 
 Freezer (-30°C) PORRKA, Hollola, Finland 
 Freezer (-86°C) Sanyo, Bad Neudorf 
 Gel Doc 2000 Bio-Rad Laboratories GmbH, 
München 
 Hotblock for Tubes HCL HBT 130, Kobe, Japan 
 Ice machine Ziegra, Isernhagen 
 Incubator Shaker New Brunswick Scientific, 
Edison, NJ, USA 
 Laser Scanning Microscope Olympus, Hamburg 
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 Liquid blocker Daido, Sangyo, Japan 
 Microscope (Olympus A×70) Olympus, Hamburg 
 Mini electrophoresis system Bio-Rad, Hercules, CA, USA 
 Mini protean II dual slab cell Bio-Rad, Hercules, CA, USA 
 Nitrocellulose membrane Schleicher-Schuell Biosci., 
Dassel 
 Pipetting aid Hirschmann, Eberstadt 
 Pipetman Gilson, Middleton, WI, USA 
 Refrigerator (+ 4°C) PORRKA, Hollola, Finland 
 Thermocycler Biometra, Göttingen 
 Thin-Certs (0.4µm) Greiner Bio-One, Frickenhausen 
 Thermal Printer DPU 414 Eppendorf, NY, USA 
 Ultraviolet Transilluminator UVP, Upland, CA, USA 
 Vortex (Genie 2) mixer Scientific Industries, Bohemia, 
NY, USA 
 xCELLigence Roche, Mannheim 
 X-ray film Agfa, Köln 
2.9 Software 
 RTCR software 1.2.1.1002 ACEA Biosciences, San Diego, 
CA, USA 
 Quantity One 4.6.2 Bio-Rad, Hercules, CA, USA 
 FlowJo 7.6.1 Tree Star, Ashland, OR, USA 
 Multiple sequence alignment MultAlin online [21], Tolouse, 
France 
 Primer premier 5.0 Premier Biosoft international, Palo 
Alto, CA, USA 
 PlasMapper online 2.0 University of Alberta, Edmonton, 
Canada [23] 
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3. Methods 
3.1 Generation of recombinant plasmids 
Full-length wild type SIVmac239-Nef cDNA (GenBank: M33262.1) and its 
mutants (M8, Y28A, Y39A, Y28A/Y39A, DE184AA, LM194AA, DD204AA and 
DE184AA/LM194AA/DD204AA) were amplified by Polymerase Chain Reaction 
(PCR) using the previously published SIVmac239-Nef constructs as templates 
[58]. Two full-length CXCR4 splice variants, CXCR4-Lo (NCBI Reference 
Sequence: NM_001008540.1) and CXCR4 (NCBI Reference Sequence: 
NM_003467.2), were derived from total RNA of HUVEC cells which are known 
to exhibit high CXCR4 expression levels. Briefly: total RNA from HUVEC cells 
was isolated with the RNeasy Mini Kit (Qiagen, Hilden, Germany) and reverse 
transcription was performed with the Transcriptor First Strand cDNA Synthesis 
Kit (Roche Applied Science, Basel, Switzerland) using 1μg of total RNA 
according to the manufacturer’s protocol. Primers for subcloning into 
pcDNA3.1(+) and pDsRed-monomer-N1 vectors (Invitrogen Corporation, 
Carlsbad, CA, USA) contained a HindIII restriction site at the 5’ end and an 
EcoRI restriction site at the 3’ end (Table 2). PCR was performed for 40 cycles 
of: 1) 95°C for 30s, 2) 56°C for 1min and 3) 72°C for 1min.  
PCR products were separated according to their size in 1% agarose gel. 
After gel purification (QIAquick Gel Extraction Kit, Qiagen, Hilden), the 
amplicon was double-digested with HindIII and EcoRI (New England Biolabs 
GmbH, Frankfurt am Main). PCR products were ligated with pcDNA3.1(+) and 
pDsRed-N1 previously linearized with the same enzymes. DH5α competent 
cells (Invitrogen Corporation, Carlsbad, CA, USA) were subsequently 
transformed with the respective vectors. After growing on Lysogeny broth (LB) 
plates in the presence of 100µg/ml ampicillin (for pcDNA3.1) or 50μg/ml 
kanamycin (for pDsRed-N1) overnight at 37°C, clones were picked and 
cultured overnight at 37°C with agitation (250rpm) in LB media containing the 
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respective antibiotic. The plasmid DNA was purified using the QIAprep Spin 
Miniprep Kit (Qiagen) and the correct insert size was confirmed by 
HindIII/EcoRI double digest and sequence analysis (4base lab GmbH, 
Reutlingen) (Fig. 4). 
 
 
Primer ID Primer sequence 
SIVmac239-Nef (WT/ M8) 
pcDNA3.1(+) 
Forward  5‘-AAACTTAAGCTTGCCACCATGGGTGGAGCTATTT-3‘ 
Reverse  5‘-TCTGCAGAATTCTCAGCGAGTTTCCTTC-3‘ 
pDsRed-N1 
Forward 5‘-GAGCTCAAGCTTGCCACCATGGGTGGAGCTATTT-3‘ 
Reverse 5‘-TCTGCAGAATTCGGCGAGTTTCCTTCTTG-3‘ 
CXCR4 /CXCR4-Lo 
Primer forward 
Forward  5‘-AAACTTAAGCTTGCCACCATGTCCATTCCT-3‘ 
Lo-Forward 5‘-AAACTTAAGCTTAGCCACCGCATCT-3‘ 
Primer reverse 
Rev. pcDNA3.1(+) 5‘-GGCTAGGAATTCCATCTGTGTTAG-3‘ 
Rev. pDsRed-N1 5‘-TCTGCAGAATTCGGCTGGAGTGAAAACTTGA-3‘ 
Table 2. Primer sequence 
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Figure 4. Generation of recombinant plasmids. (A) Subcloning of 
pcDNA3.1(+)-SIVmac239-Nef. 1) SIV-Nef PCR product; 2) HindIII/EcoRI double 
digestion of plasmid of Nef-WT; 3) HindIII/ EcoRI double digestion of plasmid of 
Nef-M8. (B) Cloning of pDsRed-N1-CXCR4. 1) PCR product amplified from 
HUVEC; 2) Nested PCR product amplified from 1:10 dilution of preceding PCR 
product; 3) HindIII/EcoRI double digestion of plasmid of pDsRed-N1-CXCR4. 
Arrow points to the respective Nef or CXCR4 DNA fragments. 
*Picture is designed by PlasMapper 2.0 software tool [23]. 
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 Reaction system 
 Reverse Transcriptase (RT) reaction system: 
RNA 1.0µg 
Oligo(dT)18-Primer (50pmol/µl) 1.0µl 
H2O   up to 13.0µl 
5x Reaction buffer   4.0µl 
Desoxynucleotid-Mix (10mM) 2.0µl 
RNAse Inhibitor (40U/µl) 0.5µl 
Reverse Transkriptase (20U/µl) 1.0µl 
 PCR reaction system: 
Red Taq Mix 2.5μl 
5`Primer (50nmol/µl) 0.5μl 
3`Primer (50nmol/µl) 0.5μl 
H2O 10.5μl 
Template 1.0μl 
  Double digest reaction system: 
 
 
 
 Ligation system: 
 
 
PCR products (plasmid) 8.0μl 
EcoRI (20U/µl) 0.5μl 
HIND III (20U/µl) 0.5μl 
10X NEB2 buffer 1.0μl 
* 37°C water bath for 1 hour.  
cDNA (gel purified) 6.5μl 
10X T4 DNA ligase buffer  1.0μl 
T4 DNA Ligase (400U/µl) 0.5μl 
Linearized vector (gel purified) 2.0μl 
* ligation overnight at 4°C.  
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3.2 STR analysis 
The cell line ACC3 used in our study was obtained from Dr. Saku (Niigata 
University School of Dentistry, Japan) [15]. It reportedly was derived from an 
adenoid cystic carcinoma [39] and exhibits high CXCR4 expression levels [68]. 
Recently it was reported [75;105] that ACC3 cells were cross-contaminated 
with HeLa cells in different laboratories world-wide. In order to verify the cell 
line used in this study, DNA was isolated from ACC3 and HeLa cell lines using 
the Blood & Cell Culture DNA Mini Kit from Qiagen (13323, Hilden) and sent to 
a commercial provider for short tandem repeat (STR) analysis (DSMZ, 
Braunschweig). The data revealed that the ACC3 cell line was most closely 
related to HeLa cells as previously reported by Phuchareon et al. [75] (Table 
3). 
Therefore to distinguish the cells used in our studies from regular HeLa 
cells, although according to the STR analysis no significant difference should 
be expected, we designated the cells as HeLa-ACC during the course of our 
study. Since HeLa cells exhibit high cell surface expression levels of CXCR4 
and were often used in research to evaluate the role of CXCR4 during the 
infection of HIV [11;93], HeLa-ACC cells should be suitable to evaluate the effect 
of SIVmac239-Nef on tumor cell proliferation, migration and angiogenesis. 
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* Data from: Phuchareon et al. [75] 
 
Source Cell Line D5 D13 D7 D16 vWA TH01 TPOX CSF1 Amel 
percent 
match to 
HeLa 
DSMZ HeLa 11,12 12, 13.3 8,12 9,10 16,18 7 8,12 9,10 X 100% 
Phuchareon et al.* HeLa 11,12 12, 13.3 8,12 9,10 16,18 7 8,12 9,10 X 100% 
Phuchareon et al.* ACC2/Sa 11,12 12, 13.3 8,12 9,10 16,17,18 7 8,12 9,10 X 97% 
Phuchareon et al.* ACC3 11,12 12, 13.3 8,12 9,10 17,18 7 8,12 9,10 X 94% 
Our study ACC3 11,12 12, 13.3 8,12 9,10 16,17,18 7 8,12 9,10 X  
Our study HeLa 11,12 12, 13.3 8,12 9,10 16,18 7 8,12 9,10 X  
Table 3. STR analysis of the ACC3 cell line used in the study 
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3.3 Cell culture and transfection 
HeLa-ACC, COS-7 [32] and MDCK-C7 [61;104] cells were cultured in 
Dulbecco's Modified Eagle Medium (DMEM) in the presence of 10% fetal calf 
serum (FCS), 1% L-glutamine, 100U/ml penicillin and 100mg/ml streptomycin 
at 37°C, 5% CO2  in a humidified atmosphere. Human Umbilical Vein 
Endothelial Cells (HUVEC, C-003-5C, Life Technologies Corporation, Carlsbad, 
CA, USA) were cultured in EGM® -2 media supplemented with growth factors 
(Lonza Group Ltd, Basel, Switzerland). The culture medium was replaced 
every 3 days and the cells were passaged when reaching 80% confluence.  
Twenty four hours before transfection, 5-10 X 105 cells were plated in 6 
well cell culture plates. Cells were transfected after reaching 90-95% 
confluence. Cells were transfected with 4.0μg plasmid DNA using 10μl 
LipofectaminTM2000 (Invitrogen Life Technologies, Karlsruhe) per well 
according to the manufacturer’s protocol (Table 4). The transfection medium 
was changed after 4-6 hours and cells were harvested 24 or 48 hours after 
transfection for further analysis. HUVEC cells were transfected using 
TransPass™ HUVEC Transfection Reagent (New England Bio Labs, Beverly, 
MA, USA) and LipofectaminTM RNAiMAX (Invitrogen Life Technologies, 
Karlsruhe) was used for siRNA transfection according to the following 
protocols (Table 5 and Table 6):
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Table 4. Transfection with LipofectaminTM 2000 
Culture 
vessel 
Surf. 
Area per 
well 
(cm
2
) 
Shared reagents  DNA transfection 
Vol. of 
plating 
medium 
(ml) 
Vol. of 
dilution 
medium 
(ul) 
DNA 
(μg) 
Lipofectamin
TM 
2000 
(μl) 
12 well 4  1  2X100  1.6  4  
6 well 10  2  2X250  4.0  10  
60mm 20  5  2X500  8.0  20  
Tab. 5 Transfection with TransPass™ V 
Culture
vessel 
Vol. of 
plating 
medium 
(per well) 
Conc. Of DNA 
in serum-free 
medium  
HUVEC Reagent 
component in 
transfection 
complex 
mixture 
TransPass V       
in transfection 
complex mixture 
12 well 1ml 1.6μg in 150μl 1-2μl 1-4.0μl 
6 well 2ml 3.0μg in 250μl 4-6μl 4-10μl 
60 mm 5ml 6.0μg in 500μl 8-12μl 8-24μl 
Tab. 6 Transfection with LipofectaminTM RNAiMAX 
Culture 
vessel 
Surf. 
Area per 
well 
(cm
2
) 
Vol. of 
plating 
medium 
(ml) 
Vol. of 
dilution 
medium 
(μl) 
siRNA 
(pmol) 
lipofectamin
TM 
RNAiMAX 
(μl) 
6 well 10  2.5  2 X 250 100  5  
60mm 20  5  2 X 500  200  10  
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3.4 SDS-PAGE and Western blot 
Forty-eight hours after transfection, cells were harvested, washed twice 
with PBS and then incubated in lysis buffer (1%NP-40, 20mM TrisCl pH 8.0, 
137mM NaCl, 10% glycerol and 2mM EDTA) supplemented with protease and 
phosphatase inhibitor (Sigma-Aldrich. Saint Louis, MO, USA) [60]. After slow 
vortex at 4°C for 30min, lysates were centrifuged at 12,000X g at 4°C for 20min. 
The supernatant containing the total protein was transferred to a new tube and 
the protein concentration was determined with the Bradford method (Bio-Rad 
Laboratories, München). 
Thirty-five µg total protein was separated by 10% sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to 
nitrocellulose membrane. The membranes were blocked in 3% milk/PBS for 1h 
at room temperature following an incubation with the primary antibodies at 4°C 
overnight. After washing with 3% milk/PBS thrice, membranes were incubated 
with an HRP-linked anti-rabbit or anti-mouse secondary antibody for 1h at 
room temperature. After washing away excessive antibody, bands were 
visualized with the enhanced chemiluminescence (ECL) method on x-ray film.  
3.5 FACS analysis 
Forty-eight hours after transfection, cells were harvested, washed twice in 
PBS/0.5% BSA and incubated with a PE-conjugated anti-CXCR4 antibody (PE 
Mouse Anti-Human CD184, BD Biosciences, San Jose, CA, USA) on ice for 1h. 
IgG2a was used as an isotype control. After wash, cell surface fluorescence 
was monitored by FACS analysis (BD LSR II, BD Biosciences, San Jose, CA, 
USA). 4’-6’-Diamino-2-phenylindole (DAPI) was added before checking and 
data analysis was performed using the FlowJo software (Tree Star, Inc., 
Ashland, OR, USA). 
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3.6 Confocal laser scanning microscopy 
HeLa-ACC and COS-7 cells growing on cover slips were transfected with 
red fluorescent protein containing constructs (pDsRed-monomer-N1-CXCR4, 
pDsRed-monomer-N1-CXCR4-Lo, pDsRed-monomer-N1-Nef or 
pDsRed-monomer-N1-Nef-M8) and incubated for 48h. Cells were washed 
thrice in PBS, fixed for 30min in methanol (-20°C). The cover slips were sealed 
with clear nail polish and fluorescence was evaluated by confocal laser 
scanning microscopy (Fluoview, Olympus Deutschland GmbH, Hamburg). 
HeLa-ACC cells that were grown on cover slips were transfected with Nef or 
control vector and incubated for 48h. Cells were washed thrice in PBS, fixed 
for 30min in methanol (-20°C) and incubated in staining buffer 
(3%BSA/0.3%NP40/PBS) for 30min. The respective anti-SIV-Nef or 
anti-CXCR4 antibodies were added (1:250) and incubated at room 
temperature for 2 more hours. Subsequently cells were washed thrice in 
staining buffer and secondary FITC-conjugated goat anti-rabbit IgG (for 
SIV-Nef) or TR-conjugated goat anti-mouse IgG (for CXCR4) were added 
(1:500) and incubated for 1h at room temperature in the dark. After washing 
thrice in staining buffer and once in water, DAPI (1:250) was added and 
incubated for 10min at room temperature. The cover slips were sealed with 
clear nail polish and subcellular localization was evaluated by confocal laser 
scanning microscopy. 
3.7 In vitro scratch assay 
HeLa-ACC cells transfected with SIVmac239-Nef-WT or control (Nef-M8/ 
vector only) were seeded in 6-well plates and cell growth was allowed to 
continue until confluence was reached. The cell monolayer was scratched with 
a 100µl pipette tip and dislodged cells were washed away with PBS. Cell 
incubation was continued under standard conditions with medium containing 
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SDF-1α (100ng/ml) and the degree of cell migration into the scraped area was 
documented in the subsequent 72 hours [52]. 
3.8 Real time cell proliferation and migration 
Tumor cell proliferation and migration was detected by the xCELLigence 
system (Roche, Mannheim, Germany). The presence of the cells on top of the 
electrodes will affect the local ionic environment at the electrode/solution 
interface, leading to an increase in the electrode impedance. The measured 
impedance, which is dependent on the level of confluence, was expressed as 
an arbitrary unit called the Cell Index (CI). The Cell Index at each time point is 
defined as (Rn-Rb)/(15Ω), where Rn is the cell-electrode impedance of the 
well when it contains cells and Rb is the background impedance of the well 
with the media alone. The increasing CI values were then recorded with the 
xCELLigence system in real-time to monitor cell proliferation and migration 
(Fig. 5.). 
5 x 103 HeLa-ACC cells, transfected with the respective plasmid, were 
suspended in 150μl DMEM media and added into a 96-well plate that is 
specifically designed to measure cellular impedance (E-Plate, Roche, 
Mannheim). The attachment, spreading and proliferation of the cells were 
monitored every 15 minutes. SDF-1α (100ng/ml) was added to the media after 
24 hours. Cells without SDF-1α were used as a negative control. Cell 
proliferation was monitored every 15 seconds for 6 hours and then every 15 
minutes until maximum impedance was reached. 
The cell monolayer was scratched when the impedance reached a 
maximum using a 10µl tip in the same way as described for the in vitro scratch 
assay above. The CI was monitored every 15 seconds for 6 hours then every 
15 minutes for 24 hours. The CI at the time of the scratch was normalized and 
the proliferation curve was analyzed with the RTCA software (1.2.1.1002, 
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Figure 5. xCELLigence system.  (A) The system consists of: real-time cell 
analysis (RTCA) Analyzer, RTCA SP Station, RTCA Control Unit and single 
use E-Plate 96. (B) Cells attaching on the top of the electrode increase the 
impedance. (C) Cell Index values, derived from the measured impedances, 
are continuously displayed with the Software.  
(Modified from www.roch-applied-science.com/sis/xcelligence/index) 
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ACEA Biosciences, San Diego, CA, USA). 
HeLa-ACC cells were transfected with SIVmac239-Nef mutants (M8, Y28A, Y39A, 
Y28A/Y39A, DE184AA, LM194AA, DD204AA and DE184AA/LM194AA/DD204AA) and 
their effects on cell proliferation were detected as described above. 
3.9 Electrical resistance breakdown assay 
The electrical resistance breakdown assay was used to measure cellular 
invasiveness. Madine-Darby canine kidney cells (MDCK) as described 
previously were used as a cellular barrier in TEER since they are able to form 
high transepithelial electrical resistance after reaching confluence [61;104]. 
The membrane filter cups having a pore size of 0.4µm and a culture surface 
of 4.25cm2 (ThinCertsTM, Greiner Bio-One, Frickenhausen) were inserted into 
a 6-well cell culture plate containing 3ml medium per well. 1 X 105 MDCK cells 
were then seeded into the filter cup to grow to confluence over 48 hours. The 
current-induced voltage change across the epithelial monolayer is displayed 
as resistance on a voltohmmeter (EVOMTM, World Precision Instruments, 
Sarasota, FL, USA). 
5 X 105 HeLa-ACC cells, 24h after transfection with Nef-WT, were seeded 
carefully on top of the MDCK monolayer. The same MDCK cells and Nef-M8 or 
vector-only transfected HeLa-ACC cells were seeded as a negative control, 
whereas highly invasive A7 Melanoma cells were used as a positive control 
[46;59;98]. All cells were grown in DMEM medium and SDF-1α (100ng/ml) was 
added to the medium of the lower chamber when cells were seed into the filter 
cups. TEER breakdown will occur, if the integrity of the MDCK monolayer is 
compromised by tumor cells [46]. 
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3.10 Matrix gel invasion assay 
Cell invasion was also measured by a matrix gel invasion assay. 24-well 
culture inserts (ThinCertTM, Greiner Bio-One, Frickenhausen) with 8µm pores 
were inserted in a 24-well plate. ECM gel was thawed overnight at 4°C. 60μl 
ECM gel solution was added to each cell culture insert and dried at room 
temperature for 1h under laminar air flow. Nef-WT and CXCR4 siRNA 
transfected HeLa-ACC cells, as well as control HeLa-ACC cells were cultured in 
serum free DMEM (contained 0.2% BSA) one night before the invasion assay. 
Cells were harvested, washed twice in PBS and resuspended in serum-free 
medium (containing 0.2% BSA) at a final concentration of 1 X 106 /ml. 200µl of 
the cell suspension was added into the upper chamber and 600μl of DMEM 
with 10% FBS and 100ng/ml SDF-1α were added into the lower chamber. 
Cells were cultured for 20h at 37°C and 5% CO2. Subsequently, the upper 
chamber was carefully taken out and the membrane was fixed in cold (-20°C) 
methanol for 30min. Then the membrane was stained with 0.5% Toluidine Blue 
for 20min at room temperature. Cells at the inner surface of the upper chamber 
were carefully wiped with a cotton swab. Invading cells were detected by light 
microscopy in the center of the bottom of the membrane and the average 
number of at least 3 fields per membrane was calculated. 
3.11 Endothelial in vitro tube formation assay 
 In vitro angiogenesis assay was used to evaluate the effects of SIV-Nef on 
HUVEC cell tube formation. HUVEC cells were transfected with SIV-Nef-WT, 
CXCR4 or CXCR4 siRNA. pcDNA3.1(+), Nef-M8 or scrambled siRNA 
transfected HUVEC cells were used as a control. Twenty-four hours after 
transfection, 1 X 106 HUVEC cells were seeded into the ECM precoated 
96-well plates and incubated at 37°C, 5% CO2. Tube formation was observed 
Methods 
- 28 -   
 
and evaluated by light microscopy 4-18 hours after seeding of the cells. 
3.12 Statistical analysis 
Nonparametric tests were used for data analysis. The Mann-Whitney test 
was implemented to evaluate the statistical significance of the proliferation 
rates between SIV-Nef-WT, Nef-M8 and vector-only transfected HeLa-ACC cells. 
A probability less than 0.05 (p<0.05) was considered statistically significant.
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4. Results
4.1 Co-expression of SIVmac239-Nef and CXCR4 
 Full length cDNAs of SIVmac239-Nef-WT, SIVmac239-Nef-M8 and CXCR4 
were subcloned into the mammalian expression vector pcDNA3.1(+) and 
pDsRed-monomer-N1 as described in the Methods section (Fig. 4). To confirm 
expression of the constructs, COS-7 cells were transfected with the respective 
plasmids and protein expression was evaluated by Western blot analysis (Fig. 
6).  
 
  
 
 
 
Figure 6. Exogenous expression of Nef and CXCR4 in COS-7 cells. 
Western blot analysis demonstrates co-expression of CXCR4 and 
Nef-WT or Nef-M8 in COS-7 cells after co-transfection of the respective 
two constructs. Cells transfected with CXCR4 and empty vector 
(control) express CXCR4 but exhibit no Nef signal, whereas 
untransfected cells do not express Nef or significant levels of 
endogenous CXCR4. No obvious change is noted in the total CXCR4 
protein level after transfection with Nef. Actin was used as an internal 
control. 
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Nef (27kDa) and CXCR4 protein (43kDa) can be detected in Nef and 
CXCR4 transfected cells. No Nef was detectable in SIV-Nef untransfected 
cells. Only minimal amounts of endogenous CXCR4 were seen in untreated 
and pcDNA3.1(+) (“vector-only”) transfected control cells. No obvious change 
in whole cellular CXCR4 protein levels was seen after co-transfection with Nef. 
Fluorescence microscopy demonstrates Nef-WT protein at the cell surface 
as well as in the cytoplasm of COS-7 cells, whereas the functionally defective 
Nef protein (Nef-M8) was found accumulated at the plasma membrane. 
CXCR4, as well as CXCR4-Lo, localize to the cell membrane, cytoplasm and 
even the nucleus (Fig. 7). 
 
 
 
 
Figure 7. Fluorescence detection of COS-7 cells transfected with 
pDsRed-N1-Nef or pDsRed-N1-CXCR4 plasmids. 
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The surface expression level of CXCR4 in COS-7 cells was detected by 
FACS analysis. Compared with untreated COS-7 cells which had little or even 
no expression of surface CXCR4 (<2%), the expression level of surface 
CXCR4 was increased to app. 20% in CXCR4 or CXCR4-Lo transfected 
COS-7 cells (Fig. 8). 
 
 
 
 
4.2 Co-transfection of CXCR4 and SIVmac239-Nef leads to down regulation 
of CXCR4 from the cell surface in COS-7 cells 
After demonstrating the expression of CXCR4 constructs in COS-7 cells, 
the same constructs were co-transfected with WT-Nef. Functionally deficient 
Nef-M8 and pcDNA3.1(+) (vector-only) were co-transfected with CXCR4 as a 
negative control. Although no change in whole cellular CXCR4 protein levels 
was detected (Fig. 6), FACS analysis revealed that cell surface fluorescence of 
CXCR4 was reduced in Nef-WT co-transfected cells, but not in Nef-M8 and 
vector-only co-transfected cells indicating a specific effect of Nef for 
down-modulation of the CXCR4 receptor from the cell surface. The reduction 
of CXCR4-Lo by Nef-WT was also detectable but not as pronounced as in 
CXCR4 transfected COS-7 cells (Fig. 9).  
Figure 8. Expression of surface CXCR4/CXCR4-Lo in transfected 
COS-7 cells was evaluated by FACS analysis. 
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Figure 9. FACS analysis of COS-7 cells co-transfected with CXCR4 and 
Nef. COS-7 co-transfected with the two CXCR4 variants (CXCR4-Lo, 
CXCR4) and Nef-WT. Nef-M8 or pcDNA3.1(+) was used as a control. 
Surface CXCR4 expression was detectable after transfection. Both CXCR4 
splice variants can be downregulated by Nef-WT, but not by Nef-M8 or vector 
control. The reduction of CXCR4-Lo by Nef-WT appeared less pronounced 
than in CXCR4 transfected cells. 
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4.3 SIVmac239-Nef down-regulates endogenous CXCR4 from the cell 
surface of CXCR4 expressing tumor cells 
In order to evaluate the effects of SIV-Nef on endogenous cell surface 
CXCR4, the CXCR4 positive tumor cell line, HeLa-ACC, was transfected with 
SIVmac239-Nef-WT or negative control (Nef-M8 or vector-only). Western blot 
analysis could detect Nef protein only in SIV-Nef transfected cells and could 
confirm high endogenous CXCR4 expression (Fig. 10). No procaspase-3 
cleavage was detectable in Nef transfected HeLa-ACC cells. Similarly as 
observed in CXCR4 transfected COS-7 cells, there was no obvious change in 
total CXCR4 protein expression levels in SIV-Nef transfected HeLa-ACC cells.      
Figure 10. Western blot analysis of Nef-WT, Nef-M8 and vector-only 
transfecetd HeLa-ACC cells. All cells -transfected and untransfected- are 
positive for endogenous CXCR4, whereas only the Nef-transfected 
cells express the viral protein. No cleaved procaspase-3 is seen in 
Nef-transfected cells. Beta-actin was used as an internal control. 
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Immunocytochemical analysis demonstrated Nef in the cytoplasm and at 
the plasma membrane. Endogenous CXCR4 was detectable in all HeLa-ACC 
cells. Interestingly, similarly as observed in CXCR4 transfected COS-7 cells, a 
CXCR4-specific signal was not only found at the plasma membrane but also in 
the cytoplasm and nucleus (Fig. 11). No obvious co-localization of Nef and 
CXCR4 was detected (Fig. 11). 
Similarly as observed for COS-7 cells, FACS analysis revealed a reduction 
of cell surface CXCR4 in Nef-transfected HeLa-ACC cells (Fig. 12).  
 
 
 
 
 
 
 
 
Figure 11. Immunocytochemical analysis of HeLa-ACC cells transfected 
with SIV-Nef. Using laser scanning microscopy, endogenous CXCR4 (TR) is 
found at the plasma membrane as well as in the cytoplasm and nucleus. 
SIV-Nef (FITC) is found at the plasma membrane and in the cytoplasm. No 
obvious co-localization of Nef and CXCR4 was detected 
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4.4 Proliferation of HeLa-ACC cells is reduced after Nef transfection 
The xCELLigence system was deployed to measure real-time cell 
proliferation and migration. HeLa-ACC cells were transiently transfected with 
SIV-Nef-WT. Nef-M8, vector-only, CXCR4 siRNA and scrambled short RNA 
were used as a control. Transfected HeLa-ACC cells were seeded into 
specialized 96-well culture plates (E-plate) and electrode impedance was 
measured continuously as described in the Methods section (Fig. 5). 
Twenty-four hours after cell seeding, SDF-1α (100ng/ml) was added to the 
medium. Vector-only transfected control cells treated with SDF-1α exhibited an 
enhanced proliferation rate compared to SDF-1α untreated cells (Fig. 13).  
 The proliferation rate of the vector control was taken as a baseline (1.0) 
and the proliferation ratio of Nef-WT and Nef-M8 compared to the vector 
control (relative proliferation rate) was plotted to highlight potential effects of 
Nef (Fig. 14A). Nef-WT transfected HeLa-ACC cells exhibited a markedly 
reduced proliferation rate in both untreated and SDF-1α treated groups, 
Figure12. FACS analysis of HeLa-ACC cells transfected with SIV-Nef. 
HeLa-ACC cells were transfected with Nef-WT and Nef-M8, pcDNA3.1(+). 
The latter two served as a negative control. 
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whereas Nef-M8 transfected cells exhibited a similar proliferation rate as the 
vector-only transfected cells, pointing to a specific effect of the viral protein on 
HeLa-ACC cell proliferation. CXCR4 siRNA transfection resulted in inhibition of 
the cells proliferation rate compared to scrambled control RNA transfected 
cells (as baseline) (Fig. 14A).  
Cell proliferation was monitored from 0 to 48 hours after cell seeding (Fig. 
14B). The cell doubling time of Nef-WT transfecetd HeLa-ACC cells significantly 
increased from 30 hours to 45 hours (p=0.02) and this effect appeared even 
more pronounced in the SDF-1α treated cells (p=0.01), indicating that SIV-Nef 
significantly inhibits cell proliferation. Nef-M8 and vector-only transfected 
HeLa-ACC cells exhibited a decrease in doubling time after incubation with 
SDF-1α, whereas Nef-WT transfected cells did not respond significantly to 
SDF-1α, which appears to be in accordance with the observed decrease of 
surface CXCR4 by SIV-Nef. 
Figure 13. HeLa-ACC cells (vector control) exhibit an enhanced proliferation 
rate after addition of 100ng/ml SDF-1α. 
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cDNA from SIVmac239-Nef M8, containing functionally relevant mutations at 
the N-terminus as well as C-terminal flexible loop [58] (Fig. 15A), was 
subcloned into pcDNA3.1(+) as described above. The construct was confirmed 
by sequence (Fig. 15A) and Western blot analyses (Fig. 15C). The effect of 
functionally deficient Nef on HeLa-ACC cell proliferation was evaluated by the 
xCELLigence system. The slope of the cell index curve was calculated and 
shown in the bar chart (Fig. 15B). Nef-M8 transfected cells have a similar 
proliferation rate as vector-only transfected cells and were used as a Nef 
negative control (set to 100%) to evaluate the effect of Nef-WT and the other 
mutants on cell proliferation (Fig. 15B). Wild type Nef on the other hand served 
as a positive control. As expected, Nef-WT decreased proliferation of 
transfected HeLa-ACC cells to 41% of negative control values (M8). The Y39AA 
mutant Nef showed a similar efficiency as Nef-WT (49%), whereas the Y28A 
(81%), DE184AA (62%), LM194AA (73%) and the triple mutation protein 
DELMDD (DE184AA/LM194AA/DD204AA) (83%) Nef mutant lost most of their 
ability to inhibit cell proliferation. Interestingly, the DD204AA (102%) mutant 
exhibited an inhibition of cell proliferation comparable to Nef-M8. 
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Figure 14. Nef from SIVmac239 inhibits proliferation of HeLa-ACC cells. A) The 
relative proliferation rate of Nef-WT and Nef-M8 transfected HeLa-ACC cells 
relative to the vector only transfected control cells, that were normalized to 1.0, 
reveals a significant (p=0.02 at 48h) inhibition of proliferation in the Nef-WT 
transfected cells. This effect appeared even more pronounced in the SDF-1α 
treated cells (p=0.01 at 48h). CXCR4 siRNA transfected HeLa-ACC cells also 
exhibited an obvious inhibition of proliferation rate compared to scrambled RNA 
(as baseline). B) Doubling time of transfected HeLa-ACC cells with and without 
SDF-1α treatment.  
A
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Figure 15. Effects of SIVmac239-Nef mutations on cell proliferation. A) Location 
of Nef mutations in different endocytic motifs (modified from Mandic et al. Mol 
Biol Cell, 2001). Constructs were confirmed by sequence analysis. B) Effect of 
mutations in SIVmac239-Nef on cell proliferation. Nef-M8 transfected HeLa-ACC cells 
were used as a negative control (set to 100%) and the ratio for the Nef mutants 
was calculated relative to this value. Nef-WT served as a positive control. C) 
Expression of transfected SIV-Nef was confirmed by Western blot analysis. 
ß-actin was used as an internal control.  
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4.5 Migration is inhibited in SIVmac239-Nef transfected CXCR4
+ tumor cells 
An in vitro scratch assay was performed to evaluate the potential influence 
of Nef on cellular migration. Cell numbers were normalized for better 
comparison. After scratching the cell layer with a pipette tip, the subsequent 
rise in impedance was the lowest in the Nef-transfected HeLa-ACC cells 
compared with vector-only or Nef-M8 transfected cells pointing to Nef as an 
inhibitor of cell migration in HeLa-ACC (Fig. 16A). Considering the doubling time 
to be around 30-50 hours, the short time required for impedance to rise after 
scratching the cell layer indicates that migration rather than proliferation is 
likely responsible for this effect. Microscopical analysis of HeLa-ACC cells show 
a different rate of cells moving into the cell free scratched region. Nef-WT 
transfected cells displayed the lowest migratory ability compared with Nef-M8 
or vector control pointing to an inhibitory effect of Nef on cell migration (Fig. 
16B). 
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Figure 16. Nef from SIVmac239 inhibits migration of HeLa-ACC cells. A) 
Real-time cellular analysis reveals a quick increase of electric impedance 
after scratching Nef-M8 and vector control, but not Nef-WT transfected 
HeLa-ACC cells. B) Microscopical analysis shows cells migrating into the cell 
free scratched surface area. Nef-WT transfected HeLa-ACC cells exhibit 
reduced migratory abilities compared to control cells. 
Results 
- 42 -   
 
4.6 Effects of SIVmac239-Nef on CXCR4
+ tumor cell invasiveness 
Five х 105 Nef-WT, Nef-M8 and vector-only transfected HeLa-ACC cells, as 
well as untreated HeLa-ACC cells were applied on top of the MDCK monolayer. 
A7 melanoma cells served as a positive control whereas MDCK cells were 
used as a negative control. The electric resistance was measured over the 
following days (Fig. 17A). A reduction in TEER was observed in A7 melanoma 
cells within 3 days, whereas no obvious TEER was seen in the MDCK cells. 
Nef-WT transfected cells didn’t show a reduction of TEER compared with 
Nef-M8 and vector-only control indicating that the Nef protein has no effect on 
invasiveness of HeLa-ACC cells in this specific assay.  
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Figure 17A. Transepithelial electrical resistance breakdown (TEER) 
assay. SIVmac239-Nef transfected HeLa-ACC cells did not exhibit enhanced 
invasiveness compared to control cells.  
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A similar result was also observed in a transwell invasion assay. No 
significant reduction of invasiveness can be detected in Nef-WT and CXCR4 
siRNA transfected HeLa-ACC cells compared with vector-only (not shown), 
Nef-M8 or scrambled RNA transfected cells (Fig.17B). 
 
Figure 17B. Transwell invasion assay. No significant reduction 
of invasiveness can be observed in Nef-WT and CXCR4 siRNA 
transfeceted cells compared with M8, scrambled RNA or vector 
transfected cells. 
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4.7 In vitro tube formation of endothelial cells is reduced after 
transfection with SIVmac239-Nef  
In order to evaluate if SIV-Nef has an effect on angiogenesis, HUVEC cells 
were transfected with Nef-WT and CXCR4 siRNA. Untreated, Nef-M8, vector 
only or scrambled siRNA transfected cells were used as a negative control. 
Their tube formation abilities were evaluated by an in vitro tube formation 
assay as described above. Nef-WT transfected HUVEC cells, as well as 
CXCR4 siRNA transfected cells, demonstrated an inhibition of tube formation 
compared with Nef-M8 transfected cells (Fig. 18). Nef-M8 transfected HUVEC 
cells formed capillary structures similarly to untransfected and vector only 
transfected control cells (not shown).  
HUVEC cells were also transfected with the two CXCR4 variants 
(CXCR4-Lo, CXCR4). Interestingly, CXCR4 over expression in HUVEC cells 
resulted in loss of most of its in vitro tube formation ability, whereas tube 
formation appeared similar between Nef-M8 control and CXCR4-Lo 
transfected HUVEC cells (Fig. 18).  
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Figure 18. Nef inhibits angiogenesis. Nef-WT transfected HUVEC cells 
lost most of their in vitro tube formation ability compared with control cells 
(M8). A similar effect is observed after CXCR4 knockdown with siRNA. 
Overexpression of CXCR4 in HUVEC cells also inhibits tube formation.  
Results 
- 46 -   
 
4.8 SIVmac239-Nef affects SDF-1α/CXCR4 signaling in CXCR4
+ tumor cells 
The MAPK/ERK pathway is activated by the SDF-1/CXCR4 axis, which 
communicates signals from cell surface to the nucleus to activate transcription 
of genes involved in the regulation of chemotaxis, proliferation or apoptosis. To 
determine whether SIV-Nef has an effect on the MAPK/ERK pathway in tumor 
cells, Nef-WT transfected HeLa-ACC cells were treated with SDF-1α (100ng/ml). 
Cells were lysed 0, 5, 10 and 30min after incubation with the CXCR4 ligand. 
Phospho-STAT3, phosphorylated ERK1/2 and procaspase-3 cleavage were 
evaluated by Western blot analysis. Beta-actin was used as an internal control. 
 Higher levels of phospho-ERK1/2 were detected in Nef-WT transfected 
HeLa-ACC cells, which declined following treatment with SDF-1α. On the 
contrary, increased expression levels of phospho-ERK1/2 were detected in 
vector-only (Fig. 19) as well as Nef-M8 (data not shown) transfected cells. 
However, this effect was not pronounced. 
 
 Figure 19. SIV-Nef inhibits MAPK/ERK signaling. 
Results 
- 47 -   
 
 Compared with vector-only transfected control cells, a sharp decrease in 
STAT3 phosphorylation at 10min was detectable in Nef-WT transfected cells 
indicating that SIV-Nef affected phosphorylation of STAT3 (Fig. 20). No effect 
on procaspase-3 cleavage could be observed in Nef expressing and 
vector-only control cells, whereas cyclin-D1 was inhibited after transfection 
with Nef (Fig. 21). β-actin was used as an internal control. 
 
 
 
 
 
 
Figure 20. Enhanced inhibition of phospho-STAT3 in Nef-WT transfected 
HeLa-ACC cells. The expression of phospho-STAT3 in Nef transfected tumor 
cells was decreased after 10 min of treatment with SDF-1α, whereas the same 
reduction was visible 30 min after ligand treatment in control cells. No 
procaspase-3 cleavage was detectable in both vector and Nef transfected cells. 
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Figure 21. Cyclin-D1 is decreased in Nef transfected HeLa-ACC cells. 
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5. Discussion 
Nef is a 27 kDa, N-terminal myristoylated HIV/SIV accessory protein. During 
the process of infection with HIV/SIV, Nef is down modulating MHC class I 
molecules from the cell surface of infected cells, is reducing MHC class II 
levels in antigen presenting cells (APCs) and CD8 levels in cytotoxic T 
lymphocytes [13;29;85;87] thereby promoting immune escape of the virus 
[20;22]. Nef also down regulates cell surface CXCR4, a major co-receptor of 
CD4, which is required for virus entry, to prevent lethal viral superinfection of 
the infected cell [29;58;94]. CXCR4 not only is known as a co-receptor for 
HIV/SIV entry but is also involved in malignant transformation, proliferation, 
migration and metastasis. It plays an important role in directing metastatic 
CXCR4+ cells to organs that express high SDF-1α levels [53;67-69;106]. 
Therefore, targeting the CXCR4 receptor, e.g. with a CXCR4 inhibiting peptide 
such as ALX40-4C, is used as a therapeutic approach to prevent HIV/SIV 
infection as well as tumor metastasis [3;24].  
In the present study wild-type Nef from SIVmac239, which previously was 
shown to exhibit a potent down-modulating effect on CXCR4 in Jurkat T cells, 
was used to transfect CXCR4 positive tumor cells (HeLa-ACC) to investigate if 
this viral protein also affects CXCR4 levels and related tumor relevant 
parameters such as proliferation, invasion and migration. 
In HeLa-ACC cells, CXCR4 was found located at the plasma membrane as 
well as in the cytoplasm and nucleus. This is in accordance with previous 
reports that found a correlation of cytoplasmic and nuclear CXCR4 expression 
with lymph node metastasis and reduced overall survival in breast cancer and 
non-small cell lung cancer patients [70;102]. One explanation for the observed 
high level of intracellular CXCR4 could be a concomitant expression of SDF-1α 
since autocrine secretion of the ligand could result in enhanced endocytosis of 
the receptor with subsequent cytoplasmic and nuclear localization. Indeed, 
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co-expression of CXCR4 and SDF-1α was found to predict lymph node 
metastasis in colorectal cancer [103].  
Transfection of HeLa-ACC cells with Nef resulted in down-regulation of 
CXCR4 from the cell surface, however, without markedly influencing CXCR4 
total protein expression. Real-time cellular analysis of Nef transfected cells 
revealed that tumor cells transfected with the viral protein had a significantly 
reduced proliferation and migration rate. Recently, it was found that CXCR4 is 
closely involved in tumor angiogenesis. In vitro tube formation analysis 
displayed that HUVEC cells transfected with SIV-Nef partly lost their tube 
formation ability which not only indicated the important role of CXCR4 in 
angiogenesis but also a potential role of SIV-Nef for inhibition of tumor 
angiogenesis.   
CXCR4/SDF-1α activates numerous intracellular signaling pathways to 
regulate cellular chemotaxis, migration, proliferation, apoptosis and adhesion. 
The MAPK/ERK pathway is the main signaling pathway stimulated by the 
activation of CXCR4/SDF-1α [41;56;84;90]. ERK can phosphorylate and 
activate downstream cellular protein, such as STAT3 [43;49;54;99], leading to 
changes in gene expression and cell cycle progress. ERK was found relatively 
inhibited in SIV-Nef expressing HeLa-ACC cells in response to the treatment of 
SDF-1α compared with Nef absent cells. STAT3, located downstream of ERK, 
was found markedly inhibited pointing to an influence of Nef on the MAPK/ERK 
pathway. Since activation of STAT3 is related to proliferation, cyclin-D1 
expression was evaluated by Western blot analysis. Cyclin-D1 was found 
reduced in SIV-Nef expressing HeLa-ACC cells. Therefore, SIV-Nef could inhibit 
HeLa-ACC cell proliferation by a delay in cell cycle progression. This result is in 
accordance with a similar observation in CD4+ T cells [71]. No signs of 
apoptosis such as cleavage of procaspase-3 could be observed in any of the 
Nef-transfected cells (Fig.10; Fig.20) thereby not confirming that the SIV-Nef 
inhibiting effect exerted on HeLa-ACC cells is necessarily related to 
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programmed cell death as previously reported for HIV-1 Nef in Jurkat cells [60]. 
Nef affects intracellular signaling through a complex, not fully understood 
mechanism. STAT3 was phosphorylated or activated from a crosstalk way 
such as mTOR or JAKs. ERK was reportedly increased and PI3K was inhibited 
by HIV-Nef in Jurkat T cells as well as primary peripheral CD4+ T lymphocytes 
[16]. The effect of Nef on intracellular signaling is a subject for further studies. 
Wild type but not mutated HIV-1-Nef was previously found to induce 
apoptosis in Jurkat T cells [6]. Subsequent mapping of Nef could reveal two 
specific regions (motifs) in the HIV-1-Nef sequence that exert apoptosis, with 
motif 1 (M1) being the most powerful one [42]. Interestingly, in a recent article 
this group used a Nef peptide (Nef-M1) representing the pro-apoptotic motif 1 
to treat four colorectal cancer cell lines as well as colorectal xenografts in SCID 
mice. Here, they could observe a potent anti-tumor effect and concluded that 
the interaction of the Nef-M1 peptide with CXCR4 is responsible for the 
observed effect [38]. However, no obvious sequence similarities with these two 
HIV-Nef apoptosis inducing motifs can be found in SIVmac239-Nef. 
Motifs in the N-terminus and C-terminal flexible loop of SIVmac239-Nef were 
found to be important for internalization of the viral protein [58]. In our study, 
the mutation Y28A (at the N-terminus) and DE184AA, LM194AA, DD204AA (in the 
C-terminal flexible loop) lead to a reduction of cellular proliferation, indicating 
that these motifs in SIV-Nef play a role in regulating cell surface CXCR4 and 
tumor cell proliferation. 
CXCR4-Lo is a transcript variant of CXCR4, which contains a longer 
N-terminus when compared to CXCR4. CXCR4-Lo reportedly could be a 
competitor of CXCR4 for its binding to SDF-1α. Few studies focused on 
CXCR4-Lo since its discovery in 1999 [36]. Its function relative to CXCR4 
remains unclear. In order to better understand if CXCR4-Lo is also sensitive to 
SIV-Nef down regulation, CXCR4-Lo was expressed in COS-7 cells. 
CXCR4-Lo localized to the cell membrane, cytoplasm and even the nucleus in 
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RFP-CXCR4-Lo transfected COS-7 cells similarly as observed for CXCR4. 
SIV-Nef could down regulate cell surface CXCR4-Lo but as it appears to a 
smaller extent than CXCR4. Influence on proliferation in CXCR4-Lo 
transfected HeLa-ACC cells was not obvious (data not shown). The data 
indicates that CXCR4 could play a major role in SIV-Nef mediated inhibition of 
tumor cell proliferation and migration. Interestingly, CXCR4 overexpressing 
HUVEC cells showed a reduction of in vitro tube formation ability. The 
transfection of one of the CXCR4 isoforms potentially could break the balance 
between the two variants thereby affecting angiogenesis. The mechanism 
behind this effect is currently unknown and subject to ongoing studies. 
Since CXCR4/SDF-1α plays such an important role in tumor growth, many 
anti-SDF-1α or anti-CXCR4 directed agents such as AMD3100, NOX-A12 or 
CCX2066 were developed and used in preclinical in vivo studies partly 
demonstrating a significant decrease in tumor growth [14;44;72;81]. Our data 
indicate that Nef from SIVmac239 can down-modulate plasma membrane 
associated CXCR4 in CXCR4+ tumor cells and that expression of the viral 
protein could further result in reduction of tumor cell proliferation, migration and 
angiogenesis. SIV-Nef therefore could serve as an interesting experimental 
tool for the study of CXCR4-expressing tumors and potentially could help to 
pinpoint new therapeutic approaches for the treatment of these malignancies.
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6. Summary 
The HIV/SIV accessory protein Nef is known to down-modulate cell surface 
receptors that are required for virus entry such as CD4, CCR5 and CXCR4 to 
block lethal viral superinfection of the infected cell. The chemokine receptor 
CXCR4 also plays an important role in promoting tumor cell proliferation, 
metastasis and angiogenesis. Therefore it was of interest to evaluate if Nef can 
down-regulate CXCR4 in tumor cells since this could affect these critical 
prognostic parameters. The CXCR4+ tumor cell line HeLa-ACC was transfected 
with Nef from SIVmac239 and cell surface expression of the receptor was 
monitored by FACS analysis. Real-time cellular analysis was performed and 
cell migration was evaluated by an in vitro scratch assay. The in vitro tube 
formation assay was carried out on Nef transfected HUVEC cells to evaluate if 
Nef affects angiogenesis. Also, the influence of Nef on intracellular signaling 
was evaluated by Western blot analysis. Additionally, COS-7 cells were 
co-transfected with Nef and CXCR4 or its transcript variant, CXCR4-Lo, and 
were treated in the same way as described for HeLa-ACC. 
In this study, cell surface down-modulation of endogenous CXCR4 could be 
observed in HeLa-ACC cells after Nef-transfection as well as in COS-7 cells 
after co-transfection of CXCR4 and Nef. Proliferation as well as migration of 
Nef-transfected HeLa-ACC tumor cells was significantly reduced. Nef 
transfected HUVEC cells lost most of their tube formation ability. The CXCR4 
transcript variant, CXCR4-Lo, could also be down-regulated by Nef in COS-7 
cells. Interestingly, a reduced tube formation ability was observed in CXCR4 
overexpressed HUVEC cells, whereas CXCR4-Lo transfected HUVEC cells 
displayed similar tube formation levels compared to the vector control 
transfected cells. 
Our data demonstrated that Nef from SIVmac239 can down-modulate plasma 
membrane associated CXCR4 in a CXCR4+ tumor cell line (HeLa-ACC). 
Transfection of HeLa-ACC or HUVEC cells resulted in reduction of tumor cell 
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proliferation, migration and angiogenesis. SIV-Nef therefore could serve as an 
interesting experimental tool for the study of CXCR4-expressing tumors and 
potentially could help to pinpoint new therapeutic approaches for the treatment 
of these malignancies.
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8. Appendix 
8.1 Abbreviations 
AIDS Acquired immunodeficiency syndrome 
APCs Antigen presenting cells 
APS Ammoniumpersulphate 
BSA Bovine serum albumin 
CI Cell index 
CXCR4 C-X-C chemokine receptor type 4 
DAPI 4',6'-diamidino-2-phenylindole, dihydrochloride 
DMEM Dulbecco’s Modified Eagle Medium 
DMSO Dimethylsulfoxide 
DNase Deoxyribonuclease 
ECL Enhanced chemiluminescence 
ECM Extracellular Matrix 
EDTA Ethylene diaminetetraacetic acid 
ERK Extracellular signal regulated kinases 
FCS Fetal calf serum 
FITC Fluorescein isothiocyanate 
JAKs Janus Kinase 
HRP Horseradish peroxidase 
HIV-1(HIV-2) Human immunodeficiency viruses 1 (or 2) 
kDa Kilodalton 
MDCK-C7 Madine-Darby canine kidney cell-clone 7 
mTOR mammalian target of rapamycin 
MW Molecular weight 
NP40 Nonidet P 40 substitute 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate buffered saline 
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PCR Polymerase Chain Reaction 
rpm Revolutions per minute 
SDF-1α Stromal cell-derived factor-1α 
SDS Sodium-Dodecyl-Sulphate 
SIV Simian immunodeficiency virus 
STAT 3 Signal transducer and activator of transcription 3 
STR Short tandem repeat analysis 
TEER Transepithelial electrical resistance 
TEMED N, N, N', N'-tetramethyl ethylenediamine 
WT Wild type 
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8.2 Table index 
Table 1  11 
Table 2   15 
Table 3   19 
Table 4   21 
Table 5  21 
Table 6  21 
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8.3 Figure index 
Figure 1  2 
Figure 2  3 
Figure 3  4 
Figure 4  16 
Figure 5  25 
Figure 6  29 
Figure 7  30 
Figure 8  31 
Figure 9  32 
Figure 10  33 
Figure 11  34 
Figure 12  35 
Figure 13  36 
Figure 14  38 
Figure 15  39 
Figure 16  41 
Figure 17A  42 
Figure 17B  43 
Figure 18  45 
Figure 19  46 
Figure 20  47 
Figure 21  48 
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8.4 Presentations 
 “Differential expression of VEGF-A isoforms in angiomas and 
squamous cell carcinoma cell lines of the head and neck area.”  
2nd International Symposium on Hemangiomas and Vascular 
Malformations of the Head and Neck, Little Rock, USA, 2009. 
 “SIV Nef as a new therapeutic approach in head and neck cancer.”  
Workshop zur klinischen und experimentellen Forschung in der 
Kopf-Hals-Onkologie, Leipzig, Germany, 2011.  
 “Implications of SIV-Nef in antiangiogenesis.” 
3rd International Symposium on Hemangiomas and Vascular 
Malformations of the Head and Neck, Marburg, Germany, 2011. 
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8.8 Ehrenwörtliche Erklärung 
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